Proton Pump Inhibitor
14
1
1
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
36%
5 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
Optimizing Medications and Lung Health in People With HIV Through Pharmacist-led Proactive E-Consults
Potassium-Competitive Acid Blocker Versus Proton Pump Inhibitor as A Part of Bismuth Based Quadruple Therapy for Treatment of Helicobacter Pylori Infection
Therapeutic Effect of Vonoprazan Versus Dexlansoprazole in Treatment of Gastroesophageal Reflux Disease
Proton Pump Inhibitors (PPI): a Study to Improve Appropriate Prescriptions in the Elderly
Patient Journey Application for Discontinuing Inappropriate PPI Use: a Randomized Controlled Trial
Risk Factors and Machine Learning Model for Proton Pump Inhibitor Related Acute Kidney Injury
Evaluation of the Long-term Tolerance of Proton Pump Inhibitor (PPI) Discontinuation in Geriatric Patients Treated With Long-term Therapy Without a Recognized Indication
A RCT of the Efficacy of Vonoprazan 20mg QD in the Treatment of Helicobacter Pylori Infection
On-demand PPI Therapy is Effective on Controlling Symptoms in Patients With Barrett's Esophagus.
Evaluation of Rebound Effect After Withdrawal of Proton Pump Inhibitor in Geriatric Population
Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft
Sup-Icu RENal (SIREN)
An Open-Label Trial of Dexlansoprazole 60mg for the Relief of Heartburn During the Fasting Month of Ramadan
Effects of Enteral Nutrition on Stress Ulcer Hemorrage. Multicenter Randomized Controlled Trial